4 Unique Challenges of Oncology Trials
Oncology trials face unique hurdles in innovation, enrollment, and endpoints, requiring strategic planning to address complex study demands and precision needs.
Oncology trials face unique hurdles in innovation, enrollment, and endpoints, requiring strategic planning to address complex study demands and precision needs.
Gene therapy research requires both IRB and IBC oversight—while IRBs protect participants, IBCs ensure community and environmental safety with local site-specific reviews.
In clinical trials, the safety of research participants is paramount. An organization conducting or sponsoring clinical research can ensure participant
The study startup process is a critical point in research, and oftentimes, can make or break a study’s success.
IVDs diagnose and monitor health using biospecimens, often in labs. FDA-regulated but varied in compliance, IVDs require careful IRB review preparation.
The Food and Drug Administration’s (FDA’s) proposed single institutional review board (sIRB) mandates are in part designed to support greater
Regulations for research involving devices, in vitro diagnostics (IVDs), and digital therapeutics differ from those governing pharmaceutical development. While drugs
The Food and Drug Administration (FDA) recently released new guidance regarding cellular and gene therapy products, one of which may
Having a one in four chance of developing sickle cell disease (SCD) is uniquely, and overwhelmingly, familiar to the African
How do you know your experimental therapy is working? Sometimes, it can be as simple to determine as comparing drug
Metrics in general are one of the ways we can gauge how well a program or service delivers. In the
New privacy regulations seem to form every few months, especially with individual U.S. states adopting their own privacy regulations (e.g.,